PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 140 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2017. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $582,000 | -27.5% | 54,053 | -14.4% | 0.12% | -30.8% |
| Q2 2019 | $803,000 | -38.0% | 63,142 | +89.2% | 0.17% | -93.9% |
| Q1 2019 | $1,295,000 | +142.5% | 33,378 | +27.1% | 2.76% | +2927.5% |
| Q4 2018 | $534,000 | -18.1% | 26,259 | +84.6% | 0.09% | +35.8% |
| Q3 2018 | $652,000 | -16.8% | 14,227 | +7.4% | 0.07% | -90.3% |
| Q2 2018 | $784,000 | +26.2% | 13,252 | +45.2% | 0.69% | +28.6% |
| Q1 2018 | $621,000 | -35.0% | 9,129 | -5.5% | 0.54% | -55.0% |
| Q4 2017 | $955,000 | +92.2% | 9,661 | +133.0% | 1.20% | +1688.1% |
| Q3 2017 | $497,000 | +51.1% | 4,147 | +10.1% | 0.07% | +36.7% |
| Q2 2017 | $329,000 | +8.6% | 3,767 | -53.8% | 0.05% | -9.3% |
| Q1 2017 | $303,000 | +34.1% | 8,147 | +10.6% | 0.05% | -20.6% |
| Q4 2016 | $226,000 | -56.0% | 7,366 | -3.9% | 0.07% | -72.7% |
| Q3 2016 | $514,000 | +125.4% | 7,666 | 0.0% | 0.25% | +47.3% |
| Q2 2016 | $228,000 | +132.7% | 7,666 | +130.8% | 0.17% | +25.2% |
| Q1 2016 | $98,000 | – | 3,321 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
| Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
| Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
| Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
| GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
| Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
| Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
| ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |